Announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration on April 16, 2026, to discuss a potential registrational development path in anal cancer. Oncolytics Biotech Inc shares N.ONCY are trading up $0.02 at $0.98.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=6862717115706380